US sells Wu-Tang Clan album to cover Shkreli debt; OrbiMed backs GSK vets' Chinese startup
Martin Shkreli became a top target for ridicule and anger in the mid-2010s when he and his biotech Turing Pharmaceuticals raised the price of a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
